Avid Bioservices Inc (CDMO)

[north40000]

Biopharm, I wonder whether this company's filter device could be adapted to filter PS-bearing proteins, virus, cells(?) from a system:

...Time Magazine Names The Aethlon Hemopurifier® One of the 25 Best Inventions of 2014

Date : 11/21/2014 @ 7:15AM
Source : PR Newswire (US)
Stock : NO^AEMD (AEMD)
Quote : 0.687 0.1665 (31.99%) @ 12:30PM


Aethlon Medical, Inc. (USOTC:AEMD)


SAN DIEGO, Nov. 21, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® has been named one of the 25 best inventions of 2014 by Time Magazine. The article can be found on-line at the following link: http://time.com/3594971/the-25-best-inventions-of-2014

Aethlon Hemopurifier.

The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. To date, the device has been utilized in the treatment of Ebola, HIV and Hepatitis C virus. Time previously reported on the successful use of Hemopurifier® therapy in an Ebola patient with multiple organ failure. The article can be found on-line at the following link: http://time.com/3586271/ebola-treatment-dialysis-blood

About Aethlon Medical, Inc.

Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.